Municipality of Ikast-Brande strengthens its addiction services with Monsenso

Municipality of Ikast-Brande strengthens its addiction services with Monsenso

Copenhagen, Denmark – 17 January 2019. Monsenso, a Danish healthtech company focused on mobile health solutions for mental health, is proud to announce our newest collaboration with the Center for Rusmiddelbehandling in the municipality of Ikast-Brande. The aim of the pilot project is to examine how the Monsenso mhealth solution can be used as an integrated part of the addiction treatment, across both alcohol and substance misuse.

The project, which will be running from January 2019 to January 2020, will primarily involve people in outpatient treatment. This is the first step in implementing the solution more broadly throughout the center’s services, widening the scope and population that they can reach, and ultimately benefitting the people living in the municipality.

The aim of the project is to evaluate the clinical and financial benefits of using the Monsenso Solution. This is relevant for clients currently receiving treatment and for clients who have completed their treatment and are part of the post-treatment service, where it is crucial not to fall back into old and undesired habits.

With the help of the Monsenso solution and the data that are being reported directly by the client, the clinician will be able to personalise the treatment to fit each client’s needs, as they have knowledge of the client’s issues over time. It also allows for clinicians to be more proactive and reach out to clients at the time they need help in order to avoid potential relapses.

Thomas Lethenborg, CEO of Monsenso ApS, says: “The Center for Rusmiddelbehandling in Ikast-Brande strives to enhance the quality of their services by implementing the newest technology. Addiction services are an interesting growth area for Monsenso, and we are convinced that implementing our solution will be beneficial to both clients and clinicians. Moreover, the collected data are opening up a number of exciting and innovative opportunities relating to addiction treatment.”

Mette Christensen, the Head of the Center for Rusmiddelbehandling, says: “We are implementing this new technology in our addiction services to improve the quality of the treatment we can provide. At the same time, we get to be more pro-active and understand our clients better, which will profit both them and the entire municipality. The clinicians are motivated to try a different working method, so we look forward to getting started”.

Click here to read the press release in Danish.

About Center for Rusmiddelbehandling
Center for Rusmiddelbehandling (CFR) is Ikast-Brande municipality’s offer of counselling, treatment and prevention of alcohol and substance misuse. The center currently has 20 employees with different educational backgrounds, which provides a wide range of competences. CFR offers both outpatient alcohol and substance treatment, day treatment and substitution therapy.
For more information visit

About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit

For further information about Monsenso contact:
Thomas Lethenborg
+45 21298827

Monsenso partnered with University of Cambridge to support research into individuals with intellectual disabilities

Monsenso partnered with University of Cambridge to support research into individuals with intellectual disabilities

Monsenso has partnered with the University of Cambridge, Department of Psychiatry, to support the research of using mHealth to help identify the possible causes of behavioural problems for those with intellectual disabilities.

The University plans to further their research and advance their understanding of behavioural problems in individuals with intellectual disabilities, which will initially include a  group of people with Prader-Willi Syndrome. The study will be focusing on recording of information & data relating to their mental health state and try to elucidate the reasons for the behavioural problems.

Professor Tony Holland, Chair in Learning Disabilities in the Department of Psychiatry at the University of Cambridge said: “In the field of learning disabilities, we are asking questions like: “How do we detect poor mental health and behavioural problems early on?” By applying new technological solutions, such as Monsenso, we can not only improve how we collect data, but also how we can identify signatures that are an indication of poor mental health and behavioural problems.”

The Monsenso mHealth solution is used in a growing number of mental health innovation and research related studies. Monsenso is delighted to be working with Prof. Holland and team. The solution will be employed to monitor individuals and collect behavioural and physiological data via the smartphone delivered solution. The solution will collect daily self-assessment data, diary entries and record physiological measures, complemented by passive data collection by both the smartphone and wearable devices. This aim of the study is to use this data to determine the effectiveness of treatment on a number of physiological measures, and to compare physiological measures between groups of participants. Additionally, this study also wishes to see if this data can potentially identify triggers, or causes, of the behavioural problems of participants.

In previous similar research studies, clinicians, nurses and researchers were also asked to collect data about the client’s mental state and outbursts. However, this data was pen-and-paper based, which was clearly vulnerable to inaccuracies, as it was dependent upon the nurse’s ability to remember and record the events as soon as they occurred. It was also difficult for these notes to provide a longitudinal picture of the client’s behaviour over time. Applience of the technological solutions is a massive advancement in how researchers utilise and collect research data in this complex setting.

“Research is essential to find out which treatment and interventions work better for the patients and our mHealth solution can be used to enhance data collection and outcome measures that support this. Using this technology, Monsenso can help provide a detailed longitudinal overview about the individual’s mental state, which can help to identify signatures of behavioural patterns, and even forecast future conditions. We are proud to support the researchers of the University of Cambridge”, says Thomas Lethenborg, CEO of Monsenso.